RP collaboration funding announced

Article

The National Neurovision Research Institute (NNRI) in the US and Adeona Pharmaceuticals Inc. have announced a collaboration to investigate the oral drug flupirtine in the treatment of retinitis pigmentosa (RP).

The National Neurovision Research Institute (NNRI) in the US and Adeona Pharmaceuticals Inc. have announced a collaboration to investigate the oral drug flupirtine in the treatment of retinitis pigmentosa (RP).

NNRI will fund preclinical trials of flupirtine, which has been administered to approximately 27 patients across Europe for five years to treat RP, in several animal models at the Bascom Palmer Eye Institute, Miami, Florida, US.

If the preclinical trial outcomes are positive, Adeona and NNRI will potentially move on to clinical testing.

Recent Videos
3 experts are featured in this series.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.